104.18
price up icon1.10%   1.13
pre-market  Pre-market:  103.82   -0.36   -0.35%
loading
Abbott Laboratories stock is currently priced at $104.18, with a 24-hour trading volume of 4.56M. It has seen a +1.10% increased in the last 24 hours and a -1.54% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $102.5 pivot point. If it approaches the $104.3 resistance level, significant changes may occur.
Previous Close:
$103.05
Open:
$103.38
24h Volume:
4.56M
Market Cap:
$181.24B
Revenue:
$40.33B
Net Income/Loss:
$5.63B
P/E Ratio:
35.44
EPS:
2.94
Net Cash Flow:
$4.92B
1W Performance:
+1.81%
1M Performance:
-1.54%
6M Performance:
-8.21%
1Y Performance:
-3.09%
1D Range:
Value
$103.06
$104.64
52W Range:
Value
$89.67
$121.64

Abbott Laboratories Stock (ABT) Company Profile

Name
Name
Abbott Laboratories
Name
Phone
(224) 667-6100
Name
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
Employee
114,000
Name
Twitter
@AbbottNews
Name
Next Earnings Date
2024-07-18
Name
Latest SEC Filings
Name
ABT's Discussions on Twitter

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date Action Analyst Rating Change
May-30-24 Initiated Goldman Buy
Jul-21-23 Upgrade Wolfe Research Underperform → Peer Perform
May-30-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-20-23 Reiterated Barclays Overweight
Apr-20-23 Reiterated Bernstein Outperform
Apr-20-23 Reiterated JP Morgan Overweight
Apr-20-23 Reiterated Raymond James Outperform
Apr-20-23 Reiterated UBS Buy
Apr-20-23 Reiterated Wolfe Research Underperform
Mar-29-23 Initiated UBS Buy
Oct-26-22 Initiated Mizuho Neutral
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Hold
Jul-06-22 Initiated Wolfe Research Underperform
Mar-02-22 Resumed BofA Securities Buy
Jan-27-22 Reiterated Credit Suisse Outperform
Jan-27-22 Reiterated Morgan Stanley Overweight
Jan-27-22 Reiterated Raymond James Outperform
Jan-27-22 Reiterated UBS Buy
Dec-10-21 Initiated RBC Capital Mkts Outperform
Oct-27-21 Upgrade Atlantic Equities Neutral → Overweight
Oct-14-21 Initiated Redburn Neutral
May-25-21 Initiated Barclays Overweight
Apr-15-21 Initiated Atlantic Equities Neutral
Jan-28-21 Upgrade BTIG Research Neutral → Buy
Sep-11-20 Initiated Wolfe Research Outperform
Jun-01-20 Downgrade Goldman Neutral → Sell
Mar-05-20 Initiated Citigroup Buy
Feb-13-20 Initiated Goldman Neutral
Feb-06-20 Resumed BTIG Research Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Jun-13-19 Reiterated BofA/Merrill Buy
Feb-07-19 Reiterated BofA/Merrill Buy
Jan-02-19 Downgrade Citigroup Neutral → Sell
Nov-30-18 Upgrade Goldman Neutral → Buy
Oct-16-18 Initiated Barclays Overweight
Jun-27-18 Initiated Bernstein Outperform
Jan-30-18 Reiterated Citigroup Neutral
Jan-25-18 Reiterated Stifel Buy
Jan-25-18 Upgrade William Blair Mkt Perform → Outperform
Jan-03-18 Initiated Evercore ISI Outperform
Jan-02-18 Upgrade JP Morgan Neutral → Overweight
Jan-02-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-19-17 Reiterated RBC Capital Mkts Outperform
Oct-19-17 Reiterated Stifel Buy
View All

Abbott Laboratories Stock (ABT) Financials Data

Abbott Laboratories (ABT) Revenue 2024

ABT reported a revenue (TTM) of $40.33 billion for the quarter ending March 31, 2024, a -2.84% decline year-over-year.
loading

Abbott Laboratories (ABT) Net Income 2024

ABT net income (TTM) was $5.63 billion for the quarter ending March 31, 2024, a -3.00% decrease year-over-year.
loading

Abbott Laboratories (ABT) Cash Flow 2024

ABT recorded a free cash flow (TTM) of $4.92 billion for the quarter ending March 31, 2024, a -27.85% decrease year-over-year.
loading

Abbott Laboratories (ABT) Earnings per Share 2024

ABT earnings per share (TTM) was $3.21 for the quarter ending March 31, 2024, a -2.43% decline year-over-year.
loading

Abbott Laboratories Stock (ABT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Funck, Jr. Robert E.
EXECUTIVE VICE PRESIDENT
May 10 '24
Option Exercise
47.00
10,097
474,559
221,438
Funck, Jr. Robert E.
EXECUTIVE VICE PRESIDENT
May 10 '24
Sale
104.57
10,097
1,055,819
211,341
Earnhardt Lisa D
EXECUTIVE VICE PRESIDENT
May 07 '24
Sale
106.25
22,852
2,428,119
61,462
Salvadori Daniel Gesua Sive
EXECUTIVE VICE PRESIDENT
Mar 01 '24
Sale
118.50
963
114,116
125,697
ALLEN HUBERT L
EXECUTIVE VICE PRESIDENT
Mar 01 '24
Sale
118.50
853
101,080
184,806
Morrone Louis H.
EXECUTIVE VICE PRESIDENT
Mar 01 '24
Sale
118.50
801
94,918
62,968
Earnhardt Lisa D
EXECUTIVE VICE PRESIDENT
Mar 01 '24
Sale
118.50
694
82,239
84,314
Moreland Mary K
EXECUTIVE VICE PRESIDENT
Mar 01 '24
Sale
118.50
676
80,106
91,260
MCCOY JOHN A. JR.
VICE PRESIDENT
Mar 01 '24
Sale
118.50
472
55,932
18,760
Wainer Andrea F
EXECUTIVE VICE PRESIDENT
Feb 23 '24
Option Exercise
59.94
12,500
749,250
91,204
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
medical_devices SYK
$338.09
price up icon 0.22%
medical_devices BSX
$76.89
price down icon 0.29%
medical_devices MDT
$78.07
price up icon 1.31%
medical_devices EW
$92.85
price down icon 0.99%
$112.66
price up icon 1.69%
Cap:     |  Volume (24h):